Finally, evidence strength varied widely: while approved anti-obesity medications such as GLP-1 receptor agonists and combination therapies are supported by multiple large-scale randomized trials, natural and investigational products rely on limited short-term data. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.